Therapeutic Agent Testing
Therapeutic Agent Testing - Related Videos
07:10
Orthotopic Xenografting of Human Luciferase-Tagged Malignant Peripheral Nerve Sheath Tumor Cells for in vivo Testing of Candidate Therapeutic Agents
0 Views •
Cited by 17 •
2011
A method for reliably grafting luciferase-tagged human malignant peripheral nerve sheath tumor cells into the sciatic nerve of immunodeficient mice is described. The use of bioluminescence imaging to demonstrate proper establishment of tumor grafts and criteria for random segregation of animals into study groups are also discussed.
02:24
Microinjection-Based Delivery of a Therapeutic Agent into an Awake Rodent Brain
0 Views •
2025
Source: Poland, R. et al. Rodent Brain Microinjection to Study Molecular Substrates of Motivated Behavior. J. Vis. Exp. (2015)In this video, a water-filled microinjection setup consisting of a syringe and microinjector tubing is used for precise drug delivery. A rat with a pre-implanted guide cannula undergoes targeted brain microinjection, enabling accurate administration of therapeutic agents in awake animals with minimal tissue damage.
04:48
Intracranial Cannular Implantation in a Mouse to Deliver Therapeutic Agents to Brain Tumors
0 Views •
2025
This video presents a procedure for intracranial cannula implantation in a brain tumor mouse model, to facilitate the administration of an immunotherapeutic agent. The delivery of glypican-2-specific chimeric antigen receptor T cells in the tumor microenvironment triggers T cell activation, resulting in tumor lysis and tumor regression.
07:53
Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
0 Views •
Cited by 8 •
2016
The most commonly used method for nanostructured lipid carrier (NLC) synthesis involves oil-in-water emulsion, homogenization and solidification. This was modified here by applying high shear dispersion after solidification to achieve a NLC with desirable size, improved drug encapsulation and drug loading efficiency as a potential carrier for dacarbazine delivery.
05:55
Delivery of Therapeutic Agents Through Intracerebroventricular (ICV) and Intravenous (IV) Injection in Mice
0 Views •
Cited by 122 •
2011
This article demonstrates two very different methods of injection: 1) into the brain (intracerebroventricular) and 2) systemic (intravenous) to introduce the therapeutic agents into the central nervous system of neonatal mice.
FAQs
Suitable controls provide a reference point for judging whether observed changes are associated with the treatment rather than with other conditions. By comparing treatment effects with control outcomes, investigators can interpret efficacy more reliably and identify whether a result reflects a meaningful pharmacological response. This comparison strengthens conclusions drawn from experimental models and controlled clinical trials.
Dose and pharmacological response are evaluated together to understand how a treatment affects the body under different dosing conditions. Testing also includes monitoring for adverse events and potential risks, so investigators can weigh beneficial effects against unwanted responses. These findings help refine dosing decisions and determine whether the agent warrants further development or clinical consideration.
Progression depends on evidence gathered across laboratory studies and experimental models before controlled clinical trials assess the treatment in people. Investigators consider the agent’s observed efficacy, safety findings, pharmacological responses, adverse events, and potential risks. A consistent body of evidence can support advancement, while limitations or unfavorable findings may restrict further development.
Evaluating a therapy across different conditions and populations shows whether its effects remain consistent or vary with the setting in which it is used. Patient outcomes and treatment responses can expose limitations that may not appear in earlier studies. This information helps researchers refine drug development and supports more informed evidence-based treatment selection in medicine.
The process commonly moves from laboratory studies and experimental models to controlled clinical trials. Early work examines pharmacological responses, efficacy, safety, and potential risks, while later human studies monitor adverse events and patient outcomes under controlled conditions. Each stage contributes evidence for deciding whether a treatment should progress, be refined, or face limitations in development.
Results from testing provide information about treatment effects, safety, appropriate dosing, adverse events, and patient outcomes. Clinicians and researchers can use this evidence to compare therapeutic options and recognize limitations rather than relying only on theoretical expectations. In medicine, that process supports treatment selection and helps improve the effectiveness and safety of patient care.